<!DOCTYPE html>
<html lang="zh-Hant">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>松瑞藥 (4167.TW) 互動分析報告</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <!-- Application Structure Plan: 
        The SPA is structured with a top navigation bar for easy access to key sections: 
        1.  總覽 (Overview): Quick snapshot – company name, stock code, current (mock) price, overall rating, brief intro.
        2.  公司剖析 (Company Analysis): Business model, market position, subsidiaries.
        3.  核心產品 (Core Products): Ertapenem, Meropenem, market trends.
        4.  CDMO夥伴進展 (CDMO Partner Progress): Detailed updates on Iterum and Spero.
        5.  財務快照 (Financial Snapshot): Interactive charts for key financial metrics (revenue, EPS, margins), highlighting one-time gains.
        6.  估值與策略 (Valuation & Strategy): P/E, P/B, peer comparison, target price, investment recommendations.
        7.  展望與風險 (Outlook & Risks): Growth drivers, catalysts, and risks.
        This thematic, non-linear structure allows users to quickly find information relevant to them, enhancing usability compared to a linear report. Each section starts with an introductory paragraph.
    -->
    <!-- Visualization & Content Choices:
        - Overview: Text summaries, key metric cards (HTML/Tailwind). Goal: Quick Info.
        - Company Analysis: Structured text (HTML/Tailwind). Goal: Foundational Knowledge.
        - Core Products: Text descriptions, market share callouts (HTML/Tailwind). Goal: Inform on revenue drivers.
        - CDMO Partners: Structured text for each client (Drug, Status, Market Potential, Savior's Role) (HTML/Tailwind). Goal: Highlight growth area.
        - Financial Snapshot: Line/Bar charts (Chart.js) for revenue, EPS (with toggle for adjusted view), margins. Key figures as text. Goal: Analyze financial trends.
        - Valuation & Strategy: Text display for P/E, P/B, target price. HTML table for peer comparison. Goal: Investment decision support.
        - Outlook & Risks: Bulleted lists (HTML/Tailwind). Goal: Summarize pros/cons.
        Interactions include navigation, chart tooltips, and a toggle for EPS view. This approach aims for clarity and engagement.
    -->
    <style>
        body {
            font-family: 'Inter', 'Noto Sans TC', sans-serif; /* Added Noto Sans TC for better Chinese character rendering */
        }
        .chart-container {
            position: relative;
            width: 100%;
            max-width: 600px; /* Default max-width, can be overridden by Tailwind */
            margin-left: auto;
            margin-right: auto;
            height: 300px; /* Base height */
            max-height: 400px;
        }
        @media (min-width: 768px) { /* md breakpoint */
            .chart-container {
                height: 350px;
            }
        }
        .nav-link {
            padding: 0.5rem 1rem;
            border-radius: 0.375rem;
            transition: background-color 0.3s ease, color 0.3s ease;
            font-weight: 500;
        }
        .nav-link.active, .nav-link:hover {
            background-color: #0D9488; /* Teal-600 */
            color: white;
        }
        .section-title {
            font-size: 1.75rem; /* text-2xl */
            font-weight: 700; /* bold */
            color: #1F2937; /* gray-800 */
            margin-bottom: 1rem;
            border-bottom: 2px solid #0D9488; /* Teal-600 */
            padding-bottom: 0.5rem;
        }
        .card {
            background-color: white;
            border-radius: 0.5rem;
            box-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.1), 0 2px 4px -1px rgba(0, 0, 0, 0.06);
            padding: 1.5rem;
            margin-bottom: 1.5rem;
        }
        .tab-button {
            padding: 0.5rem 1rem;
            border-radius: 0.375rem;
            cursor: pointer;
            background-color: #F3F4F6; /* gray-100 */
            color: #374151; /* gray-700 */
            margin-right: 0.5rem;
            font-weight: 500;
        }
        .tab-button.active {
            background-color: #0D9488; /* Teal-600 */
            color: white;
        }
        .tooltip-custom {
            background-color: rgba(0,0,0,0.7);
            color: white;
            padding: 8px;
            border-radius: 4px;
            font-size: 0.875rem;
        }
    </style>
</head>
<body class="bg-gray-50 text-gray-800">

    <header class="bg-slate-100 shadow-md sticky top-0 z-50">
        <nav class="container mx-auto px-4 sm:px-6 lg:px-8">
            <div class="flex items-center justify-between h-16">
                <div class="flex items-center">
                    <span class="font-bold text-xl text-sky-700">松瑞藥 (4167.TW)</span>
                </div>
                <div class="hidden md:block">
                    <div class="ml-10 flex items-baseline space-x-1 lg:space-x-2">
                        <a href="#overview" class="nav-link text-gray-700 hover:bg-sky-600 hover:text-white">總覽</a>
                        <a href="#company-analysis" class="nav-link text-gray-700 hover:bg-sky-600 hover:text-white">公司剖析</a>
                        <a href="#core-products" class="nav-link text-gray-700 hover:bg-sky-600 hover:text-white">核心產品</a>
                        <a href="#cdmo-partners" class="nav-link text-gray-700 hover:bg-sky-600 hover:text-white">CDMO夥伴</a>
                        <a href="#financials" class="nav-link text-gray-700 hover:bg-sky-600 hover:text-white">財務快照</a>
                        <a href="#valuation" class="nav-link text-gray-700 hover:bg-sky-600 hover:text-white">估值與策略</a>
                        <a href="#outlook-risks" class="nav-link text-gray-700 hover:bg-sky-600 hover:text-white">展望與風險</a>
                    </div>
                </div>
                <div class="md:hidden">
                    <button id="mobile-menu-button" class="text-gray-700 hover:text-sky-600 focus:outline-none">
                        <svg class="h-6 w-6" fill="none" viewBox="0 0 24 24" stroke="currentColor">
                            <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16m-7 6h7" />
                        </svg>
                    </button>
                </div>
            </div>
        </nav>
        <div id="mobile-menu" class="md:hidden hidden bg-slate-50">
            <a href="#overview" class="block nav-link text-gray-700 hover:bg-sky-600 hover:text-white">總覽</a>
            <a href="#company-analysis" class="block nav-link text-gray-700 hover:bg-sky-600 hover:text-white">公司剖析</a>
            <a href="#core-products" class="block nav-link text-gray-700 hover:bg-sky-600 hover:text-white">核心產品</a>
            <a href="#cdmo-partners" class="block nav-link text-gray-700 hover:bg-sky-600 hover:text-white">CDMO夥伴</a>
            <a href="#financials" class="block nav-link text-gray-700 hover:bg-sky-600 hover:text-white">財務快照</a>
            <a href="#valuation" class="block nav-link text-gray-700 hover:bg-sky-600 hover:text-white">估值與策略</a>
            <a href="#outlook-risks" class="block nav-link text-gray-700 hover:bg-sky-600 hover:text-white">展望與風險</a>
        </div>
    </header>

    <main class="container mx-auto px-4 sm:px-6 lg:px-8 py-8">
        
        <section id="overview" class="mb-12 pt-16 -mt-16">
            <h2 class="section-title">投資總覽</h2>
            <div class="card">
                <p class="text-lg text-gray-700 mb-4">
                    松瑞製藥 (4167.TW) 正處於營運轉型的關鍵時期。其核心培南類抗生素業務，特別是厄他培南，在全球需求強勁及部分原廠供應不穩的背景下，展現成長動能。公司2025年第一季EPS達1.22元，但受一次性廠房處分收益顯著影響。本應用程式將深入解析松瑞藥的業務、財務、CDMO進展及投資前景。
                </p>
                <div class="grid grid-cols-1 md:grid-cols-3 gap-4 text-center">
                    <div class="bg-sky-50 p-4 rounded-lg shadow">
                        <p class="text-sm text-sky-700 font-semibold">目前股價 (模擬)</p>
                        <p class="text-2xl font-bold text-sky-900">新台幣 21.0 元</p>
                        <p class="text-xs text-gray-500">(截至 2025年5月下旬)</p>
                    </div>
                    <div class="bg-teal-50 p-4 rounded-lg shadow">
                        <p class="text-sm text-teal-700 font-semibold">目標價區間</p>
                        <p class="text-2xl font-bold text-teal-900" id="targetPriceOverview">16.2 - 24.2 元</p>
                    </div>
                    <div class="bg-amber-50 p-4 rounded-lg shadow">
                        <p class="text-sm text-amber-700 font-semibold">投資評級</p>
                        <p class="text-2xl font-bold text-amber-900" id="ratingOverview">中性偏多</p>
                    </div>
                </div>
            </div>
        </section>

        <section id="company-analysis" class="mb-12 pt-16 -mt-16">
            <h2 class="section-title">公司剖析</h2>
            <div class="card">
                <p class="text-gray-700 mb-6">松瑞製藥專注於無菌原料藥及針劑藥品的研發與製造，是全球培南類抗生素的主要供應商之一。公司具備從API到製劑的垂直整合能力，並積極拓展CDMO業務及透過子公司實現多元化發展。以下將探討其核心競爭力、市場地位及子公司佈局。</p>
                
                <div class="mb-6">
                    <h3 class="text-xl font-semibold text-gray-700 mb-2">業務版圖與核心競爭力</h3>
                    <p class="text-gray-600">松瑞藥成立於2004年，核心業務為培南類抗生素的生產與銷售，是全球前三大供應商。公司擁有從無菌原料藥到製劑成品(FDF)的垂直整合能力，核心技術在於無菌結晶與粉末滅菌處理。廠房通過多國藥監機構cGMP認證。近年策略轉型聚焦高毛利厄他培南，拓展CDMO業務，並優化營運效率（如出售竹南廠）。</p>
                </div>
                <div class="mb-6">
                    <h3 class="text-xl font-semibold text-gray-700 mb-2">全球培南類抗生素市場地位</h3>
                    <p class="text-gray-600">美洛培南及厄他培南在美國市場已佔有雙位數市佔率。厄他培南因技術門檻高及原廠供應緊張，成為關鍵成長引擎。全球培南市場預計穩定成長(CAGR 4.5-4.78%)。松瑞藥成功打入美國GPO供應鏈，並拓展中國等新市場。</p>
                </div>
                <div>
                    <h3 class="text-xl font-semibold text-gray-700 mb-2">子公司業務發展</h3>
                    <ul class="list-disc list-inside text-gray-600 space-y-1">
                        <li><strong>松瑞生技：</strong>專注利基型學名藥API、針劑開發及CRO服務，佈局胜肽藥物、寡核苷酸及mRNA領域。</li>
                        <li><strong>瑞澤生技：</strong>從事保健品及藥品銷售，推出自有品牌「SLC」系列保健食品，拓展大健康消費市場。</li>
                    </ul>
                </div>
            </div>
        </section>

        <section id="core-products" class="mb-12 pt-16 -mt-16">
            <h2 class="section-title">核心產品分析</h2>
            <div class="card">
                <p class="text-gray-700 mb-6">松瑞藥的核心產品為厄他培南與美洛培南等培南類抗生素。這些產品在全球抗生素市場中扮演重要角色，尤其在治療重症感染方面。本節將深入分析各主要產品的市場需求、競爭格局及未來展望。</p>

                <div class="mb-6">
                    <h3 class="text-xl font-semibold text-gray-700 mb-2">厄他培南 (Ertapenem)</h3>
                    <p class="text-gray-600 mb-1"><strong>市場需求與競爭：</strong>全球需求強勁，一度供不應求。美國市佔逾20%，透過Sandoz、Apotex進入GPO。台灣因原廠MSD產能緊張，松瑞藥市佔已超越原廠，預計達五成以上。</p>
                    <p class="text-gray-600 mb-1"><strong>中國市場拓展：</strong>注射劑已於2025年4月獲NMPA批准，與華潤九新簽訂獨家銷售合約，預期貢獻顯著營收。</p>
                    <p class="text-gray-600"><strong>產能佈局：</strong>已建置第二條產線，計劃2025下半年提交新增產線變更申請以擴大產能。</p>
                </div>
                <div class="mb-6">
                    <h3 class="text-xl font-semibold text-gray-700 mb-2">美洛培南 (Meropenem)</h3>
                    <p class="text-gray-600">全球前三大供應商，美國市佔雙位數。竹南廠停產出售後，原料藥改為外購，旨在優化成本結構，提升製劑毛利率。公司資源可能更集中於厄他培南及CDMO。</p>
                </div>
                <div>
                    <h3 class="text-xl font-semibold text-gray-700 mb-2">全球碳青黴烯類抗生素市場趨勢</h3>
                    <p class="text-gray-600">2022年市場規模約36.2億美元，預計2030年達52.4億美元 (CAGR 4.7-4.78%)。成長動力來自細菌抗藥性、重症感染增加及高齡化。北美為最大市場，亞太區成長最快。</p>
                </div>
            </div>
        </section>

        <section id="cdmo-partners" class="mb-12 pt-16 -mt-16">
            <h2 class="section-title">CDMO夥伴進展</h2>
            <div class="card">
                 <p class="text-gray-700 mb-6">CDMO業務是松瑞藥未來重要的成長引擎。公司目標成為培南類藥物開發及代工的首選夥伴，並已在口服固體制劑方面取得進展。本節將重點分析與Iterum Therapeutics及SPERO Therapeutics的合作案最新進度及其對松瑞藥的潛在影響。</p>
                <div id="cdmoTabs" class="mb-4">
                    <button class="tab-button active" data-tab="iterum">Iterum Therapeutics (ORLYNVAH™)</button>
                    <button class="tab-button" data-tab="spero">SPERO Therapeutics (Tebipenem HBr)</button>
                    <button class="tab-button" data-tab="otherCDMO">其他合作與產能</button>
                </div>

                <div id="iterumContent" class="tab-content">
                    <h3 class="text-xl font-semibold text-gray-700 mb-2">Iterum Therapeutics PLC (ORLYNVAH™ - Sulopenem)</h3>
                    <p class="text-gray-600 mb-1"><strong>新藥申請進度：</strong>口服培南抗生素ORLYNVAH™已於2024年10月25日獲美國FDA批准，用於治療成人女性單純性泌尿道感染(uUTIs)，是FDA批准的首款口服培南類抗生素。</p>
                    <p class="text-gray-600 mb-1"><strong>市場潛力：</strong>針對抗藥性或治療選擇有限的uUTI患者。美國每年約4000萬張uUTI處方，其中約1%為抗藥性感染。</p>
                    <p class="text-gray-600"><strong>松瑞藥角色與影響：</strong>市場推斷松瑞藥為ORLYNVAH™的CDMO夥伴 (代號SLC-017)。獲批驗證松瑞藥口服培南製造能力，有望獲生產收入。此成功案例提升松瑞藥國際CDMO信譽，利於爭取新訂單。合約細節未公開，Iterum自身有對輝瑞的里程碑付款義務。</p>
                </div>
                <div id="speroContent" class="tab-content hidden">
                    <h3 class="text-xl font-semibold text-gray-700 mb-2">SPERO Therapeutics (Tebipenem HBr)</h3>
                    <p class="text-gray-600 mb-1"><strong>新藥申請進度：</strong>口服碳青黴烯抗生素Tebipenem HBr原用於cUTI，NDA於2022年6月收FDA完整回應信函(CRL)，需額外臨床研究。2022年9月Spero與GSK達成授權協議，由GSK負責後續開發。新三期臨床試驗PIVOT-PO已於2023Q4啟動，獲FDA SPA同意。</p>
                    <p class="text-gray-600 mb-1"><strong>市場潛力：</strong>若成功上市，將是美國首款治療cUTI的口服碳青黴烯抗生素，替代靜脈注射，潛力顯著。</p>
                    <p class="text-gray-600"><strong>松瑞藥角色與影響：</strong>早期報導暗示松瑞藥可能為最初CDMO夥伴 (代號SLC-029)。FDA的CRL為挫折。GSK介入重燃希望，若試驗成功且藥物獲批，松瑞藥仍有機會為製造商，但GSK的供應鏈策略可能影響最終安排，角色仍存不確定性。</p>
                </div>
                 <div id="otherCDMOContent" class="tab-content hidden">
                    <h3 class="text-xl font-semibold text-gray-700 mb-2">其他CDMO合作機會與產能佈局</h3>
                    <p class="text-gray-600 mb-1">松瑞藥積極拓展其他CDMO業務，包括與兩家日本大型藥廠分別進行API製程開發和針劑充填的合作，顯示在培南類藥物以外的CDMO領域亦有所斬獲。</p>
                    <p class="text-gray-600">產能方面，南科廠為生產重心，負責厄他培南及亞胺培南/西司他丁。為滿足厄他培南需求及CDMO訂單，持續擴充厄他培南產線，預計2025下半年提交新增產線變更申請。出售竹南廠並將美洛培南API外購，有助優化成本並將南科廠先進產能分配給高附加價值產品及CDMO項目。</p>
                </div>
            </div>
        </section>

        <section id="financials" class="mb-12 pt-16 -mt-16">
            <h2 class="section-title">財務快照</h2>
            <div class="card">
                <p class="text-gray-700 mb-6">松瑞藥近年財務表現呈現逐步改善趨勢，2024年實現營運轉折。2025年第一季因廠房處分利益，EPS表現亮眼。本節將透過圖表展示其營收、獲利能力及關鍵財務比率，並提供調整後數據以反映常續性獲利能力。</p>
                
                <div class="mb-4">
                    <label for="epsToggle" class="mr-2 font-medium text-gray-700">顯示調整後EPS (扣除一次性收益):</label>
                    <input type="checkbox" id="epsToggle" class="form-checkbox h-5 w-5 text-sky-600 rounded">
                </div>

                <div class="grid grid-cols-1 md:grid-cols-2 gap-8">
                    <div>
                        <h3 class="text-xl font-semibold text-center text-gray-700 mb-2">營業收入趨勢</h3>
                        <div class="chart-container h-64 md:h-80 max-w-lg">
                            <canvas id="revenueChart"></canvas>
                        </div>
                    </div>
                    <div>
                        <h3 class="text-xl font-semibold text-center text-gray-700 mb-2">每股盈餘 (EPS) 趨勢</h3>
                        <div class="chart-container h-64 md:h-80 max-w-lg">
                            <canvas id="epsChart"></canvas>
                        </div>
                    </div>
                    <div>
                        <h3 class="text-xl font-semibold text-center text-gray-700 mb-2">毛利率與營業利益率</h3>
                        <div class="chart-container h-64 md:h-80 max-w-lg">
                            <canvas id="marginsChart"></canvas>
                        </div>
                    </div>
                    <div>
                        <h3 class="text-xl font-semibold text-gray-700 mb-2">關鍵財務數據 (2025 Q1)</h3>
                        <ul class="list-disc list-inside text-gray-600 space-y-1">
                            <li>總資產: 42.43億元</li>
                            <li>總負債: 3.42億元</li>
                            <li>股東權益: 38.94億元</li>
                            <li>負債比率: 8.06%</li>
                            <li>每股淨值: 12.27元</li>
                            <li>營業活動現金流量 (近12月): 4.07億元</li>
                            <li id="q1ROE">報導ROE (2025 Q1): 10.38%</li>
                        </ul>
                         <p class="text-xs text-gray-500 mt-2">註: 2025 Q1 EPS 1.22元含重大一次性收益 (約0.9元)。調整後常續性EPS約0.22-0.32元。</p>
                    </div>
                </div>
            </div>
        </section>

        <section id="valuation" class="mb-12 pt-16 -mt-16">
            <h2 class="section-title">估值與投資策略</h2>
            <div class="card">
                <p class="text-gray-700 mb-6">本節將探討松瑞藥的估值水平，包括本益比、股價淨值比，並與同業進行比較。同時，根據報告分析，提供目標價估算及短中長期投資策略建議。請注意，所有估值指標均基於報告提供數據及分析，投資決策應謹慎評估。</p>
                
                <div class="grid grid-cols-1 md:grid-cols-2 gap-8 mb-6">
                    <div>
                        <h3 class="text-xl font-semibold text-gray-700 mb-2">估值指標 (截至2025年5月下旬)</h3>
                        <ul class="list-disc list-inside text-gray-600 space-y-1">
                            <li>目前股價 (模擬): 約 21.0 元</li>
                            <li>LTM EPS (含一次性收益): 1.57 元</li>
                            <li>報導本益比 (P/E): 約 13.6 倍</li>
                            <li>標準化預估全年EPS (2025): 0.9 - 1.1 元</li>
                            <li>標準化本益比 (P/E): 約 19 - 23 倍 (以21元股價及預估EPS計算)</li>
                            <li>每股淨值 (2025 Q1): 12.27 元</li>
                            <li>股價淨值比 (P/B): 約 1.71 倍</li>
                        </ul>
                    </div>
                    <div>
                        <h3 class="text-xl font-semibold text-gray-700 mb-2">目標價與評級</h3>
                        <p class="text-gray-600"><strong>目標價區間:</strong> <span class="font-bold text-teal-700 text-lg">16.2 元 - 24.2 元</span></p>
                        <p class="text-gray-600"> (基於預估標準化EPS 0.9-1.1元及目標P/E 18-22倍)</p>
                        <p class="text-gray-600 mt-2"><strong>投資評級:</strong> <span class="font-bold text-amber-700 text-lg">中性偏多</span></p>
                    </div>
                </div>

                <h3 class="text-xl font-semibold text-gray-700 mb-3">同業比較 (截至2025年5月下旬，部分數據為標準化或估算)</h3>
                <div class="overflow-x-auto">
                    <table class="min-w-full bg-white border border-gray-300">
                        <thead class="bg-gray-100">
                            <tr>
                                <th class="py-2 px-3 border-b text-left text-sm font-semibold text-gray-600">公司名稱</th>
                                <th class="py-2 px-3 border-b text-left text-sm font-semibold text-gray-600">本益比(倍)</th>
                                <th class="py-2 px-3 border-b text-left text-sm font-semibold text-gray-600">股價淨值比(倍)</th>
                                <th class="py-2 px-3 border-b text-left text-sm font-semibold text-gray-600">毛利率(%)</th>
                            </tr>
                        </thead>
                        <tbody class="text-gray-700">
                            <tr>
                                <td class="py-2 px-3 border-b">松瑞藥 (4167.TW)</td>
                                <td class="py-2 px-3 border-b">~26 (標準化)</td>
                                <td class="py-2 px-3 border-b">~1.74</td>
                                <td class="py-2 px-3 border-b">36.86 (Q1'25)</td>
                            </tr>
                            <tr>
                                <td class="py-2 px-3 border-b">神隆 (1789.TW)</td>
                                <td class="py-2 px-3 border-b">~57-60</td>
                                <td class="py-2 px-3 border-b">~1.31</td>
                                <td class="py-2 px-3 border-b">33.22 (Q1'25)</td>
                            </tr>
                            <tr>
                                <td class="py-2 px-3 border-b">台耀 (4746.TW)</td>
                                <td class="py-2 px-3 border-b">~22.5</td>
                                <td class="py-2 px-3 border-b">~1.07</td>
                                <td class="py-2 px-3 border-b">42.05 (Q1'25)</td>
                            </tr>
                            <tr>
                                <td class="py-2 px-3 border-b">中化生 (1762.TW)</td>
                                <td class="py-2 px-3 border-b">~52-101</td>
                                <td class="py-2 px-3 border-b">~0.67</td>
                                <td class="py-2 px-3 border-b">31.37 (Q1'25)</td>
                            </tr>
                             <tr>
                                <td class="py-2 px-3 border-b">生泰 (1777.TW)</td>
                                <td class="py-2 px-3 border-b">~10.5</td>
                                <td class="py-2 px-3 border-b">~1.67</td>
                                <td class="py-2 px-3 border-b">36.86 (Q1'25)</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
                <p class="text-xs text-gray-500 mt-1">資料來源：研究報告內表三，松瑞藥數據經標準化調整。</p>
                
                <div class="mt-6">
                    <h3 class="text-xl font-semibold text-gray-700 mb-2">投資策略建議</h3>
                    <p class="text-gray-600 mb-2"><strong>短期 (3-6個月):</strong> 關注市場對「標準化」獲利能力的解讀。若股價回落至目標價區間下緣 (16-18元) 或因短期雜音錯殺，可視為介入機會。關注Q2財報驗證常續性獲利。</p>
                    <p class="text-gray-600 mb-2"><strong>中期 (6-18個月):</strong> 觀察厄他培南中國銷售、Iterum ORLYNVAH™銷售貢獻、Spero/GSK Tebipenem HBr臨床結果及松瑞藥角色、新CDMO合約等催化劑實現進度。</p>
                    <p class="text-gray-600"><strong>長期 (18個月以上):</strong> 價值取決於轉型成功能否，CDMO規模化、松瑞生技利基藥品上市、培南市場優勢維持。穩定現金流與股利政策亦為觀察點。</p>
                </div>
            </div>
        </section>

        <section id="outlook-risks" class="pt-16 -mt-16">
            <h2 class="section-title">展望與風險</h2>
            <div class="card">
                <p class="text-gray-700 mb-6">松瑞藥的未來發展充滿機遇，但也伴隨著相應的風險。本節將概述其主要的成長動能、潛在的股價催化劑，以及投資者需要關注的營運與市場風險，以提供一個更全面的投資視角。</p>
                <div class="grid grid-cols-1 md:grid-cols-2 gap-8">
                    <div>
                        <h3 class="text-xl font-semibold text-teal-700 mb-2">主要成長動能與投資亮點</h3>
                        <ul class="list-disc list-inside text-gray-600 space-y-1">
                            <li>厄他培南市場領導地位與擴張 (中國市場、美國GPO)。</li>
                            <li>CDMO業務潛力顯現 (Iterum ORLYNVAH™獲批)。</li>
                            <li>獲利能力顯著改善 (產品結構優化、成本控制)。</li>
                            <li>子公司多元化發展 (松瑞生技利基藥品、瑞澤生技保健品)。</li>
                            <li>財務結構強健 (現金充裕、低負債)。</li>
                        </ul>
                    </div>
                    <div>
                        <h3 class="text-xl font-semibold text-rose-700 mb-2">營運與市場風險提示</h3>
                        <ul class="list-disc list-inside text-gray-600 space-y-1">
                            <li>核心產品依賴與競爭 (學名藥價格壓力)。</li>
                            <li>CDMO業務不確定性 (客戶藥物商業化成效、合約細節透明度)。</li>
                            <li>Spero/GSK Tebipenem HBr 臨床與合作不確定性。</li>
                            <li>市場拓展與執行風險 (中國市場推廣)。</li>
                            <li>法規遵循風險 (GMP規範)。</li>
                            <li>子公司營運成效待觀察。</li>
                            <li>利潤率維持挑戰。</li>
                        </ul>
                    </div>
                </div>
                 <div class="mt-6">
                    <h3 class="text-xl font-semibold text-sky-700 mb-2">未來股價催化劑</h3>
                    <ul class="list-disc list-inside text-gray-600 space-y-1">
                        <li>厄他培南中國銷售超預期或美國新GPO突破。</li>
                        <li>Iterum ORLYNVAH™銷售放量，帶動CDMO訂單。</li>
                        <li>Spero/GSK Tebipenem HBr臨床數據正面且確認松瑞藥生產。</li>
                        <li>宣布新的重要CDMO合作案。</li>
                        <li>松瑞生技利基藥品成功上市或達重要里程碑。</li>
                        <li>持續公佈優於預期的季度財報 (排除一次性收益)。</li>
                    </ul>
                </div>
            </div>
        </section>
    </main>

    <footer class="bg-slate-800 text-slate-300 py-8 text-center">
        <p>&copy; 2025 松瑞藥 (4167.TW) 互動分析報告. 資訊僅供參考，不構成投資建議。</p>
        <p class="text-sm">資料來源：松瑞藥研究報告與買賣策略 (ae811190-4d31-42c6-ac8c-c5a79ef664fa)</p>
    </footer>

    <script>
        const financialData = {
            years: ["2022", "2023", "2024", "2025 Q1"],
            revenue: [1265.75, 1050.28, 1217.33, 263.86], // 百萬元
            epsReported: [0.11, 0.09, 0.57, 1.22], // 元
            epsAdjusted: [0.11, 0.09, 0.57, 0.27], // 2025 Q1 調整後EPS取中間值 (0.22-0.32 -> 0.27)
            grossMargin: [10.39, 21.04, 28.49, 36.86], // %
            operatingMargin: [-7.45, -0.23, 9.77, 10.14] // %
        };

        const valuationData = {
            targetPriceLow: 16.2,
            targetPriceHigh: 24.2,
            rating: "中性偏多"
        };

        document.getElementById('targetPriceOverview').textContent = `${valuationData.targetPriceLow} - ${valuationData.targetPriceHigh} 元`;
        document.getElementById('ratingOverview').textContent = valuationData.rating;
        
        const q1ROEText = document.getElementById('q1ROE');
        if (q1ROEText) { // Ensure element exists
            // The report states 2025 Q1 reported ROE is 10.38%.
            // The report also states: "若將2025年第一季獲利標準化（扣除廠房出售利益），則單季ROE將顯著下降"
            // but doesn't give a specific adjusted ROE. So we'll show reported.
            // The table 3 also shows "~10 (標準化年化)" for ROE, which is an annualized estimate.
            // For Q1 specific, 10.38% is the reported figure.
        }


        // Mobile menu toggle
        const mobileMenuButton = document.getElementById('mobile-menu-button');
        const mobileMenu = document.getElementById('mobile-menu');
        if (mobileMenuButton && mobileMenu) {
            mobileMenuButton.addEventListener('click', () => {
                mobileMenu.classList.toggle('hidden');
            });
        }

        // Smooth scroll for nav links
        document.querySelectorAll('a[href^="#"]').forEach(anchor => {
            anchor.addEventListener('click', function (e) {
                e.preventDefault();
                const targetId = this.getAttribute('href');
                const targetElement = document.querySelector(targetId);
                if (targetElement) {
                    targetElement.scrollIntoView({
                        behavior: 'smooth'
                    });
                }
                if (mobileMenu && !mobileMenu.classList.contains('hidden')) {
                    mobileMenu.classList.add('hidden');
                }
            });
        });
        
        // Active nav link highlighting
        const sections = document.querySelectorAll('section');
        const navLinks = document.querySelectorAll('nav a.nav-link');

        window.addEventListener('scroll', () => {
            let current = '';
            sections.forEach(section => {
                const sectionTop = section.offsetTop;
                if (pageYOffset >= sectionTop - 80) { // 80px offset for sticky header
                    current = section.getAttribute('id');
                }
            });

            navLinks.forEach(link => {
                link.classList.remove('active');
                if (link.getAttribute('href').substring(1) === current) {
                    link.classList.add('active');
                }
            });
        });


        // CDMO Tabs
        const tabButtons = document.querySelectorAll('.tab-button');
        const tabContents = document.querySelectorAll('.tab-content');

        tabButtons.forEach(button => {
            button.addEventListener('click', () => {
                const tab = button.dataset.tab;

                tabButtons.forEach(btn => btn.classList.remove('active'));
                button.classList.add('active');

                tabContents.forEach(content => {
                    if (content.id === `${tab}Content`) {
                        content.classList.remove('hidden');
                    } else {
                        content.classList.add('hidden');
                    }
                });
            });
        });
        
        // Chart.js Tooltip Customization
        const tooltipTitle = (tooltipItems) => {
            return `期間: ${tooltipItems[0].label}`;
        };
        const tooltipLabel = (context) => {
            let label = context.dataset.label || '';
            if (label) {
                label += ': ';
            }
            if (context.parsed.y !== null) {
                label += context.parsed.y.toFixed(2);
                if (context.dataset.yAxisID === 'yPercentage') {
                     label += '%';
                } else if (context.dataset.label.includes('營收')) {
                    label += ' 百萬元';
                } else if (context.dataset.label.includes('EPS')) {
                    label += ' 元';
                }
            }
            return label;
        };
        
        const commonChartOptions = {
            responsive: true,
            maintainAspectRatio: false,
            plugins: {
                legend: {
                    position: 'top',
                    labels: {
                        font: { size: 10 } // Smaller legend font
                    }
                },
                tooltip: {
                    enabled: true,
                    mode: 'index',
                    intersect: false,
                    backgroundColor: 'rgba(0,0,0,0.7)',
                    titleFont: { size: 12 },
                    bodyFont: { size: 10 },
                    footerFont: { size: 9 },
                    padding: 8,
                    callbacks: {
                        title: tooltipTitle,
                        label: tooltipLabel
                    }
                }
            },
            scales: {
                x: {
                    ticks: {
                        font: { size: 10 }, // Smaller X-axis labels
                        maxRotation: 0, // Prevent label rotation
                        autoSkipPadding: 10 // Adjust padding for auto-skip
                    }
                },
                y: {
                    ticks: { 
                        font: { size: 10 }, // Smaller Y-axis labels
                        callback: function(value) { return value.toLocaleString() + (this.axis === 'yPercentage' ? '%' : ''); }
                    },
                    beginAtZero: true
                }
            }
        };
        
        const commonPercentageScaleOptions = {
             yPercentage: {
                type: 'linear',
                position: 'right',
                grid: { drawOnChartArea: false },
                ticks: { 
                    font: { size: 10 },
                    callback: function(value) { return value.toFixed(1) + '%'; }
                },
                 min: -10, // Adjusted for operating margin
                 suggestedMax: 40
            }
        };


        // Revenue Chart
        const revenueCtx = document.getElementById('revenueChart')?.getContext('2d');
        if (revenueCtx) {
            new Chart(revenueCtx, {
                type: 'bar',
                data: {
                    labels: financialData.years,
                    datasets: [{
                        label: '營業收入 (百萬元)',
                        data: financialData.revenue,
                        backgroundColor: 'rgba(59, 130, 246, 0.7)', // blue-500
                        borderColor: 'rgba(59, 130, 246, 1)',
                        borderWidth: 1
                    }]
                },
                options: {...commonChartOptions}
            });
        }

        // EPS Chart
        const epsCtx = document.getElementById('epsChart')?.getContext('2d');
        let epsChartInstance;
        if (epsCtx) {
            epsChartInstance = new Chart(epsCtx, {
                type: 'bar',
                data: {
                    labels: financialData.years,
                    datasets: [{
                        label: '每股盈餘 (元) - 報導',
                        data: financialData.epsReported,
                        backgroundColor: 'rgba(16, 185, 129, 0.7)', // emerald-500
                        borderColor: 'rgba(16, 185, 129, 1)',
                        borderWidth: 1
                    }]
                },
                options: {...commonChartOptions}
            });
        }

        const epsToggle = document.getElementById('epsToggle');
        if (epsToggle && epsChartInstance) {
            epsToggle.addEventListener('change', function() {
                if (this.checked) {
                    epsChartInstance.data.datasets[0].data = financialData.epsAdjusted;
                    epsChartInstance.data.datasets[0].label = '每股盈餘 (元) - 調整後';
                } else {
                    epsChartInstance.data.datasets[0].data = financialData.epsReported;
                    epsChartInstance.data.datasets[0].label = '每股盈餘 (元) - 報導';
                }
                epsChartInstance.update();
            });
        }
        

        // Margins Chart
        const marginsCtx = document.getElementById('marginsChart')?.getContext('2d');
        if (marginsCtx) {
            new Chart(marginsCtx, {
                type: 'line',
                data: {
                    labels: financialData.years,
                    datasets: [
                        {
                            label: '毛利率 (%)',
                            data: financialData.grossMargin,
                            borderColor: 'rgba(239, 68, 68, 1)', // red-500
                            backgroundColor: 'rgba(239, 68, 68, 0.2)',
                            tension: 0.1,
                            yAxisID: 'yPercentage'
                        },
                        {
                            label: '營業利益率 (%)',
                            data: financialData.operatingMargin,
                            borderColor: 'rgba(245, 158, 11, 1)', // amber-500
                            backgroundColor: 'rgba(245, 158, 11, 0.2)',
                            tension: 0.1,
                            yAxisID: 'yPercentage'
                        }
                    ]
                },
                options: {
                    ...commonChartOptions,
                    scales: {
                        ...commonChartOptions.scales,
                        ...commonPercentageScaleOptions
                    }
                }
            });
        }

    </script>
</body>
</html>
